Literature DB >> 16848277

Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.

Africa Holguín1, Eva Ramirez de Arellano, Pablo Rivas, Vincent Soriano.   

Abstract

The impact of HIV-1 subtype on clinical outcome following exposure to antiretroviral therapy is currently not well known. Natural polymorphisms are often present in HIV-1 non-B subtypes at positions known to be associated with drug resistance in clade B viruses. These changes might influence the emergence of drug-resistant viruses, modifying drug susceptibility and/or the virus replicative capacity. Moreover, different pathways may lead to drug resistance according to HIV-1 clade. Finally, the influence of subtype on the performance of phenotypic assays and in the interpretation of algorithms for genotypic resistance is currently a matter of debate. All these aspects explain why the response to antiretroviral therapy might vary in subjects infected with different HIV-1 clades.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16848277

Source DB:  PubMed          Journal:  AIDS Rev        ISSN： 1139-6121            Impact factor:   2.500


  19 in total

1.  Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

Authors:  Maria Mercedes Santoro; Claudia Alteri; Luigi Ronga; Philippe Flandre; Lavinia Fabeni; Fabio Mercurio; Roberta D'Arrigo; Caterina Gori; Guido Palamara; Ada Bertoli; Federica Forbici; Romina Salpini; Evangelo Boumis; Valerio Tozzi; Ubaldo Visco-Comandini; Mauro Zaccarelli; Margriet Van Houtte; Theresa Pattery; Pasquale Narciso; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-18       Impact factor: 2.205

2.  Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.

Authors:  Kimberly L Armstrong; Tun-Hou Lee; M Essex
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

3.  Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.

Authors:  Martin Stürmer; Christoph Stephan; Peter Gute; Gaby Knecht; Markus Bickel; Hans-Reinhard Brodt; Hans W Doerr; Lutz Gürtler; Pierre Lecocq; Margriet van Houtte
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

4.  Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.

Authors:  Lavinia Fabeni; Giulia Berno; Joseph Fokam; Ada Bertoli; Claudia Alteri; Caterina Gori; Federica Forbici; Desiré Takou; Alessandra Vergori; Mauro Zaccarelli; Gaetano Maffongelli; Vanni Borghi; Alessandra Latini; Alfredo Pennica; Claudio Maria Mastroianni; Francesco Montella; Cristina Mussini; Massimo Andreoni; Andrea Antinori; Carlo Federico Perno; Maria Mercedes Santoro
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

5.  Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Meiqing Lu; Peter J Felock; Vandna Munshi; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert Gomez; Neville J Anthony; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller; Ming-Tain Lai
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

6.  Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Authors:  Ming-Tain Lai; Meiqing Lu; Peter J Felock; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert M Tynebor; Thomas J Tucker; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

7.  Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Authors:  Almoustapha Issiaka Maïga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

8.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616

9.  Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational Pattern.

Authors:  Xiao-Min Zhang; Qiwei Zhang; Hao Wu; Terrence Chi-Kong Lau; Xuan Liu; Hin Chu; Ke Zhang; Jie Zhou; Zhi-Wei Chen; Dong-Yan Jin; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-09       Impact factor: 2.205

10.  Reliability of rapid subtyping tools compared to that of phylogenetic analysis for characterization of human immunodeficiency virus type 1 non-B subtypes and recombinant forms.

Authors:  Africa Holguín; Marisa López; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2008-10-08       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.